because sterility cannot be assured
Denver, CO (PRWEB) January 19, 2009
LegalView.info, the number one source for anything and everything legal on the Web, is launching a new information portal for individuals who may have been affected by the Stryker Corporation recall of nearly 322 Custom Cranial Implant Kits, which were recalled "because sterility cannot be assured," according to a the Food and Drug Administration (FDA). The cranial implant kits are used to correct face, jaw and cranium defects. The FDA considers the recall a Class I recall meaning that there is a high likeliness that a cranial implant patient could face severe injuries or even fatality if the issue is not addressed immediately.
Patients who have received the implants are advised to seek medical attention immediately as well as to contact a cranial implant recall lawyer who can offer a free legal consultation as to the details surrounding a possible cranial implant lawsuit, which could offer a return in monetary funds as compensation for victims of the defective kits. Such a return of money could provide a cranial implant victim with the appropriate resources needed to seek a new alternative to the recalled kits as well as to receive money likely needed to undergo not only physical but mental treatments for the stress endured because of the cranial implant recall.
Cranial implant kits often are provided for a rare population that suffers from skull defects. According to The International Journal of Medical Robotics and Computer Assisted Surgery, "skull defects usually create aesthetic and functional disturbances to the patient." The journal noted that cranial implants can become difficult to implement because of the potential anatomical location, which is why it becomes even more dangerous and accompanied by an extensive degree of difficulty for a patient to have a cranial implant kit recalled. Patients should consider discussing their situation and construct potential litigation involving the Stryker cranial implant recall.
LegalView also offers a multitude of other legal topics ranging from the cranial implant recall to the latest in Fosamax and Avandia dangers as well as the peanut butter recall that has caused five deaths so far among Americans.
Both Fosamax and Avandia are prescription drugs, however, each treats a different medical issue, but both have been associated with severe side effects among patients. Fosamax is an osteoporosis drug used to treat individuals who have suffered from bone density losses including postmenopausal women. However, in January, two medical journals informed patients of severe potential Fosamax side effects including the onset of jaw bone die off and the development of esophageal cancer.
Avandia, which is used to treat type 2 diabetes through the regulation of insulin levels has similarly caused the onset of osteoporosis among patients as well as an increased risk of bone fractures among women and the development of heart failure among many patients. Those who consume Avandia are encouraged to speak with their physician regarding the prescription of Avandia as well as to discuss the potential for an Avandia lawsuit with an experienced pharmaceutical attorney.
Additionally, LegalView has recently updated its peanut butter recall information portal with news of the increased risk of salmonella poisonings among consumers from the recent rash of tainted peanut butter. To learn more about the dangers associated with consumption of the peanut butter, visit http://peanut-butter.legalview.info .
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at http://www.LegalView.com.